Progress in diagnosis and treatment of parvovirus B19 infection in kidney transplant patients

doi:10.3877/cma.j.issn.2095-3216.2021.02.010

Abstract

Abstract:

Parvovirus B19 (PVB19) is a DNA virus that is universally susceptible to humans and is widely spread around the world. It is also one of the common infectious viruses after kidney transplantation. It can cause a variety of clinical diseases that are closely related to the virus characteristics and host immune status. At present, most PVB19 infections after renal transplantation at home and abroad were mainly cases reports, lacking both unified diagnostic standard and specific antiviral drugs. The main treatment of PVB19 infection is intravenous immunoglobulins, but the optimal dose and course of treatment have not yet been determined. This review aimed to help clinicians improve their understanding of PVB19 infection by reviewing relevant literature on the diagnosis and treatment of PVB19 infection in recent years, providing help for timely diagnosis and treatment.

Key words: Parvovirus B19, Kidney transplantation, Diagnosis and treatment

Fan Yang, Zhaohui Ni. Progress in diagnosis and treatment of parvovirus B19 infection in kidney transplant patients[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(02): 109-112.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.02.010

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I02/109

References 34

[1]	Hai An HP, Diem HT, Cuong NT. Parvovirus B19 associated anemia in kidney transplant recipients: a single-center experience [J]. Transplant Proc, 2019, 51(8): 2693-2696.
[2]	Porignaux R, Vuiblet V, Barbe C, et al. Frequent occurrence of parvovirus B19 DNAemia in the first year after kidney transplantation [J]. J Med Virol, 2013, 85(6): 1115-1121.
[3]	Ki CS, Kim IS, Kim JW, et al. Incidence and clinical significance of human parvovirus B19 infection in kidney transplant recipients [J]. Clin Transplant, 2005, 19(6): 751-755.
[4]	Prasad N, Novak JE, Patel MR. Kidney diseases associated with parvovirus B19, Hanta, Ebola, and Dengue virus infection: a brief review [J]. Adv Chronic Kidney Dis, 2019, 26(3): 207-219.
[5]	Ishikawa A, Yoto Y, Asakura H, et al. Quantitative analysis of human parvovirus B19 DNA in maternal and fetal serum, and amniotic fluid during an early stage of pregnancy [J]. J Med Virol, 2015, 87(4): 683-685.
[6]	Leisi R, Von Nordheim M, Ros C, et al. The VP1u receptor restricts parvovirus B19 uptake to permissive erythroid cells [J]. Viruses, 2016, 8(10): 265.
[7]	高佩娟，石运莹，普文申，等. 六例肾移植术后人细小病毒B19感染的临床特点和疗效分析[J]. 华西医学，2019, 34(7): 769-776.
[8]	Baek CH, Kim H, Yang WS, et al. Risk factors and long-term outcomes of parvovirus B19 infection in kidney transplant patients [J]. Transpl Infect Dis, 2017, 19(5): Epub ahead of print.
[9]	Gallinella G. The clinical use of parvovirus B19 assays: recent advances [J]. Expert Rev Mol Diagn, 2018, 18(9): 821-832.
[10]	Pabisiak K, Stepniewska J, Ciechanowski K. Pure red cell aplasia after kidney transplantation: parvovirus B19 culprit or coincidence [J]. Ann Transplant, 2019, 5(24): 123-131.
[11]	Ahmed W, Dogar RUH, Acharya S. Parvovirus B19: a rare cause of post-renal transplant anemia [J]. J Coll Physicians Surg Pak, 2017, 27(12): 785-187.
[12]	Cubel Garcia RC, Pereira RF, Azevedo KM, et al. Molecular diversity of human parvovirus B19 during two outbreaks of erythema infectiosum in Brazil [J]. Braz J Infect Dis, 2017, 21(1): 102-106.
[13]	Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults [J]. Arch Intern Med, 1989, 149(5): 1153-1156.
[14]	Bonvicini F, Bua G, Gallinella G. Parvovirus B19 infection in pregnancy-awareness and opportunities [J]. Curr Opin Virol, 2017, 27: 8-14.
[15]	Eid AJ, Brown RA, Patel R, et al. Parvovirus B19 infection after transplantation: a review of 98 cases [J]. Clin Infect Dis, 2006, 43(1): 40-48.
[16]	Nair V, Jandovitz N, Jhaveri KD, et al. Treatment of parvovirus B19 viremia to facilitate kidney transplantation in a patient with collapsing glomerulopathy [J]. Clin Nephrol Case Stud, 2020, 8: 41-45.
[17]	Akeda S, Takaeda C, Takazakura E, et al. Renal involvement induced by human parvovirus B19 infection [J]. Nephron, 2001, 89(3): 280-285.
[18]	Adamson-Small LA, Ignatovich IV, Laemmerhirt MG, et al. Persistent parvovirus B19 infection in non-erythroid tissues: possible role in the inflammatory and disease process [J]. Virus Res, 2014, 190: 8-16.
[19]	Razonable RR. Not the usual viral suspects: parvovirus B19, West Nile virus, and human T-cell lymphotrophic virus infections after kidney transplantation [J]. Semin Nephrol, 2016, 36(5): 428-434.
[20]	Metzgar D, Lovari R, Ray K, et al. Analytical characterization of an assay designed to detect and identify diverse agents of disseminated viral infection [J]. Clin Viro, 2014, 59(3): 177-183.
[21]	Bodewes R, Kerkhof J, Cremer J, et al. Oral fluid: non-invasive alternative for parvovirus B19 diagnosis [J]. J Clin Virol, 2019, 117: 5-10.
[22]	Plentz A, Würdinger M, Kudlich M, et al. Low-level DNAemia of parvovirus B19 (genotypes 1-3) in adult transplant recipients is not associated with anaemia [J]. J Clin Virol, 2013, 58(2): 443-448.
[23]	AST Infectious Diseases Community of Practice, Eid AJ, Chen SF. Human parvovirus B19 in solid organ transplantation [J]. Am J Transplant, 2013, 13(Suppl 4): 201-205.
[24]	Mende M, Sockel K. Parvovirus B19 infection [J]. N Engl J Med, 2018, 379(24): 2361.
[25]	Bonvicini F, Bua G, Manaresi E, et al. Enhanced inhibition of parvovirus B19 replication by cidofovir in extendedly exposed erythroid progenitor cells [J]. Virus Res, 2016, 220: 47-51.
[26]	Manaresi E, Gallinella G. Advances in the development of antiviral strategies against parvovirus B19 [J]. Viruses, 2019, 11(7): 659.
[27]	常万兴，赵亚昆，王海平，等. 肾移植术后人细小病毒B19感染的诊治体会[J]. 临床外科杂志，2020, 28(9): 882-884.
[28]	Šutová I, Chovancová Z, Litzman J. Adverse effects of immunoglobulin therapy [J]. Vnitr Lek, 2019, 65(2): 131-132.
[29]	Tiong M, Casan J, McLean C, et al. A traumatic splenic rupture following IVIg for parvovirus B19 pure red cell aplasia post renal transplant [J]. Transpl Infect Dis, 2019, 21(2): e13045.
[30]	Rosado-Canto R, Carrillo-Pérez DL, Jiménez JV, et al. Treatment strategies and outcom of parvovirus B19 infection in kidney transplant recipients: a case series and literature review of 128 patients [J]. Rev Invest Clin, 2019, 71(4): 265-274.
[31]	Rivas-Delgado A, Matutes E, Rozman M. Recurrent pure red cell aplasia in a hepatorenal transplant recipient with chronic parvovirus B19 infection [J]. Br J Haematol, 2016, 172(4): 495.
[32]	Chandramouli S, Medina-Selby A, Coit D, et al. Generation of a parvovirus B19 vaccine candidate [J]. Vaccine, 2013, 31(37): 3872-3878.
[33]	Penkert RR, Young NS, Surman SL, et al. Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease [J]. Vaccine, 2017, 35(29): 3615-3620.
[34]	Romero Starke K, Kofahl M, Freiberg A, et al. Are daycare workers at a higher risk of parvovirus B19 infection? A systematic review and meta-analysis [J]. Int J Environ Res Public Health, 2019, 16(8): 1392.

Please choose a citation manager

Content to export